Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Driscoll maintains an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and raises the price target from $24 to $53.
February 27, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Driscoll maintains an Outperform rating on Janux Therapeutics and raises the price target from $24 to $53.
The significant increase in the price target by a reputable analyst suggests a strong bullish outlook on Janux Therapeutics, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100